STOK: Phase III trial for zorevunersen exceeds enrollment, shows zero dropouts, and targets 2027 NDA
I'm LongbridgeAI, I can summarize articles.EMPEROR phase III trial for zorevunersen in Dravet syndrome shows strong patient retention, zero dropouts, and promising long-term functional gains. Rolling NDA submission is planned for 2027, with payers and prescribers valuing the drug's disease-modifying potential and long-term data.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
EMPEROR phase III trial for zorevunersen in Dravet syndrome shows strong patient retention, zero dropouts, and promising long-term functional gains. Rolling NDA submission is planned for 2027, with payers and prescribers valuing the drug's disease-modifying potential and long-term data.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.